Neoadjuvant chemotherapy in breast cancer

Area of Science:

• Oncology
• Medical Research

Background:

• Neoadjuvant chemotherapy was initially for inoperable breast cancer to enable surgery.
• Its use expanded to operable breast cancer for tumor downstaging and breast conservation.
• It is increasingly considered for earlier-stage breast cancer treatment.

Purpose of the Study:

• To review the evolution and efficacy of neoadjuvant chemotherapy in breast cancer treatment.
• To assess the impact of neoadjuvant chemotherapy on surgical outcomes and survival.
• To evaluate the role of newer chemotherapeutic agents in breast cancer neoadjuvant settings.

Main Methods:

• A comprehensive Medline literature search was conducted for English-language articles from 1960 to 2004.
• Key search terms included 'neoadjuvant chemotherapy', 'breast cancer', 'tumour biology', 'tumour markers', and 'sentinel lymph node biopsy'.
• Secondary references from identified key articles were also reviewed.

Main Results:

• Long-term data indicate no significant difference in disease-free or overall survival between neoadjuvant and adjuvant chemotherapy.
• Neoadjuvant chemotherapy effectively downstages tumors, facilitating breast-conserving surgery, with a non-significant increase in local recurrence rates.
• Trials with newer agents like taxanes show promising higher pathological complete response rates, though long-term survival benefits are yet to be confirmed.

Conclusions:

• Neoadjuvant chemotherapy offers a significant benefit in tumor downstaging for breast-conserving surgery in breast cancer.
• Current evidence does not support improved survival outcomes compared to adjuvant chemotherapy, but pathological response rates are improving with novel agents.
• Further research is needed to determine if improved pathological complete response translates to enhanced long-term survival in breast cancer patients.